Correlative scientific data from tumour biopsies in some of these studies confirm that TKIs reach their molecular targets and suppress the activity of EGFR and HER2 and downstream MAPK signalling (Spector et al, 2005). The gene discussed is EGFR; the disease is neoplasm.